Reply

Affiliations

Comment

Anna-Maria Hoffmann-Vold et al. Arthritis Rheumatol. 2019 Apr.

. 2019 Apr;71(4):655-656.

doi: 10.1002/art.40816. Epub 2019 Mar 2.

¹ Oslo University Hospital, Rikshospitalet, and University of Oslo, Oslo, Norway.

No abstract available

Comment on

CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis.
Hoffmann-Vold AM, Hesselstrand R, Fretheim H, Ueland T, Andreassen AK, Brunborg C, Palchevskiy V, Midtvedt Ø, Garen T, Aukrust P, Belperio JA, Molberg Ø. Hoffmann-Vold AM, et al. Arthritis Rheumatol. 2018 Oct;70(10):1644-1653. doi: 10.1002/art.40534. Epub 2018 Aug 30. Arthritis Rheumatol. 2018. PMID: 29687634
Questions Regarding the Value of CCL21 as a Potential Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis: Comment on the Article by Hoffmann-Vold et al.
Zhou RP, Wei X, Ma GG, Zhu F, Chen FH, Hu W. Zhou RP, et al. Arthritis Rheumatol. 2019 Apr;71(4):653-654. doi: 10.1002/art.40743. Epub 2019 Mar 1. Arthritis Rheumatol. 2019. PMID: 30281217 No abstract available.
Insufficient Evidence to Consider CCL21 a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis: Comment on the Article by Hoffmann-Vold et al.
Xu WD, Su LC, Huang AF. Xu WD, et al. Arthritis Rheumatol. 2019 Apr;71(4):654-655. doi: 10.1002/art.40819. Epub 2019 Mar 2. Arthritis Rheumatol. 2019. PMID: 30653848 No abstract available.